Recent study has suggested that the combination of PDE5 inhibitors with irbesartan is recommended for the treatment of DN because targeted modulation of PDE5 shows anti-renal fibrillary capacity and nephroprotection (58). The gene discussed is PDE5A; the disease is liver dysplastic nodule.